AbCellera Biologics Shares Rise Tuesday, Up Over 250% Year-to-Date

AbCellera Biologics Inc. shares traded higher on Tuesday. Year-to-date, the stock has gained more than 250%.

While there is no company-specific news to explain the gain, investors may be reacting to the U.S. Food and Drug Administration's approval of two Ziihera-containing combination regimens from Jazz Pharmaceuticals plc as a first-line treatment for adults with unresectable locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma.

Readers should note that in June, Jazz Pharmaceuticals announced a collaboration with AbCellera Biologics to discover next-generation T-cell engaging multispecific antibodies.

The collaboration includes a $56 million upfront payment and potential milestone payments totaling up to $792 million, which could significantly enhance Jazz's oncology portfolio as the company focuses on gastrointestinal cancers.

Technical Analysis

AbCellera Biologics currently shows strong bullish momentum, trading well above its key moving averages. The 20-day simple moving average is 36.2% higher than the 50-day simple moving average, indicating a solid uptrend that traders should watch closely.

The relative strength index is currently at 82.82, indicating AbCellera Biologics is in overbought territory. This high RSI level suggests that while momentum is strong, a pullback or consolidation could occur in the near term.

The MACD is above its signal line, indicating bullish momentum for AbCellera Biologics. This positioning suggests the current trend may continue, but traders should remain cautious of a potential reversal given the overbought RSI.

Currently, AbCellera Biologics has no clear support or resistance levels. If the stock approaches previous highs, traders should watch for breakout or reversal signals that may indicate a shift in momentum.

All of AbCellera Biologics' moving averages are trending upward, with the 50-day simple moving average above the 200-day simple moving average, reinforcing the long-term bullish trend. This setup suggests traders can expect continued strength unless there is a significant shift in price action.

Over the past 12 months, AbCellera Biologics has delivered an impressive 185.12% return, highlighting a strong upward trajectory. This performance reflects the company's solid fundamentals and market position, making it a stock worth watching for long-term investors.

ABCL price action: AbCellera Biologics stock rose 15.83% to $12.29 at the time of Tuesday's data release.